In this study, we evaluate whether the BTK inhibitor, RN486, has similar effect as ibrutinib to enhance the tumor suppression activity of chemotherapeutic agents and overcome ABCB1-mediated MDR. The gene discussed is ABCB1; the disease is neoplasm.